IRIDEX Corporation (IRIX)

NASDAQ: IRIX · IEX Real-Time Price · USD
2.054
+0.074 (3.74%)
Jul 19, 2024, 9:58 AM EDT - Market open
3.74%
Market Cap 34.06M
Revenue (ttm) 49.92M
Net Income (ttm) -10.94M
Shares Out 16.25M
EPS (ttm) -0.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 208
Open 2.045
Previous Close 1.980
Day's Range 2.045 - 2.054
52-Week Range 1.310 - 3.650
Beta 0.84
Analysts Hold
Price Target 2.00 (-2.63%)
Earnings Date Aug 8, 2024

About IRIX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retino... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Feb 15, 1996
Employees 111
Stock Exchange NASDAQ
Ticker Symbol IRIX
Full Company Profile

Financial Performance

In 2023, IRIDEX's revenue was $51.87 million, a decrease of -8.96% compared to the previous year's $56.97 million. Losses were -$9.57 million, 26.8% more than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for IRIX stock is "Hold" and the 12-month stock price forecast is $2.0.

Price Target
$2.0
(-2.63% downside)
Analyst Consensus: Hold
Stock Forecasts

News

Iridex Reports First Quarter 2024 Financial Results

MOUNTAIN VIEW, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and proc...

2 months ago - GlobeNewsWire

Iridex Reports Fourth Quarter and Full Year 2023 Financial Results

MOUNTAIN VIEW, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and pr...

4 months ago - GlobeNewsWire

Iridex Schedules Fourth Quarter and Full Year 2023 Financial Results and Update on Strategic Review Process for March 26, 2024

MOUNTAIN VIEW, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and pr...

4 months ago - GlobeNewsWire

Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust

MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation, headquartered in Mountain View, California, and Imperial College Healthcare NHS Trust in London, today announced the first ...

6 months ago - GlobeNewsWire

Iridex Launches New Iridex 532® and Iridex 577® Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma

MOUNTAIN VIEW, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation, a global leader in innovative laser-based medical systems for the treatment of eye diseases, proudly announces the US launc...

6 months ago - GlobeNewsWire

Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulation

Action Retains Full Patient Access to MicroPulse® Transscleral Laser Treatment Action Retains Full Patient Access to MicroPulse® Transscleral Laser Treatment

7 months ago - GlobeNewsWire

Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation

MOUNTAIN VIEW, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and pro...

8 months ago - GlobeNewsWire

Iridex Reports Third Quarter 2023 Financial Results and Business Update

MOUNTAIN VIEW, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and pro...

8 months ago - GlobeNewsWire

Iridex to Host Third Quarter Financial Results Conference Call on November 14, 2023

The Company also announced plans to present at Stifel Healthcare Conference The Company also announced plans to present at Stifel Healthcare Conference

8 months ago - GlobeNewsWire

Iridex to Report Third Quarter Financial Results on November 14, 2023

MOUNTAIN VIEW, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal d...

9 months ago - GlobeNewsWire

Iridex Announces Strategic Review to Unlock Shareholder Value

MOUNTAIN VIEW, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) announced today that its Board of Directors is undertaking, in consultation with its financial and legal advi...

11 months ago - GlobeNewsWire

Iridex to Report First Quarter Financial Results on May 11, 2023

MOUNTAIN VIEW, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal ...

1 year ago - GlobeNewsWire

Iridex Reports Fourth Quarter and Full Year 2022 Financial Results

Achieves Record Quarterly Glaucoma Probe Sales and 6% Full Year Revenue Growth Achieves Record Quarterly Glaucoma Probe Sales and 6% Full Year Revenue Growth

1 year ago - GlobeNewsWire

Iridex to Present at the 35th Annual Roth Conference

MOUNTAIN VIEW, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal ...

1 year ago - GlobeNewsWire

Iridex Introduces New Research and Showcases Five Events at the AGS Meeting

Five Events at Booth #5

1 year ago - GlobeNewsWire

Iridex to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023

MOUNTAIN VIEW, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal d...

1 year ago - GlobeNewsWire

Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2022

Achieves Record Quarterly Glaucoma Probe sales and 6% Full Year Revenue Growth Achieves Record Quarterly Glaucoma Probe sales and 6% Full Year Revenue Growth

1 year ago - GlobeNewsWire

Iridex to Participate in Fireside Chat with Stifel Equity Research

MOUNTAIN VIEW, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal d...

1 year ago - GlobeNewsWire

Iridex Showcases its Non-Incisional Treatments for Glaucoma, Introduces Sweep Management Software, and Hosts 8 Physician Presentations at AAO 2022

MicroPulse® Transscleral Laser Therapy (TLT), continuous-wave transscleral cyclophotocoagulation (CW-TSCPC), and MicroPulse Laser Trabeculoplasty (MLT) are non-incisional treatments that expand ways t...

1 year ago - GlobeNewsWire

Iridex to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

MOUNTAIN VIEW, Calif., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal d...

2 years ago - GlobeNewsWire

Iridex Announces Second Quarter 2022 Financial Results

MOUNTAIN VIEW, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended July 2, 2022.

2 years ago - GlobeNewsWire

Iridex to Report Second Quarter 2022 Financial Results on August 15, 2022

MOUNTAIN VIEW, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal d...

2 years ago - GlobeNewsWire

Iridex Obtains Regulatory Clearance for Cyclo G6® Glaucoma Platform in China

MOUNTAIN VIEW, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal d...

2 years ago - GlobeNewsWire

Iridex Announces First Quarter 2022 Financial Results

Achieved Record First Quarter Revenue Achieved Record First Quarter Revenue

2 years ago - GlobeNewsWire

Iridex to Report First Quarter 2022 Financial Results on May 12, 2022

MOUNTAIN VIEW, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal ...

2 years ago - GlobeNewsWire